CoChat

Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells

Open access
Hou, Zhi-Jie, Luo, Xi, Zhang, Wei, Peng, Fei, Cui, Bai, Wu, Si-Jin, Zheng, Fei-Meng, Xu, Jie, Xu, Ling-Zhi, Long, Zi-Jie, Wang, Xue-Ting, Li, Guo-Hui, Wan, Xian-Yao, Yang, Yong-Liang, Liu, Quentin · 2015 · Oncotarget
Cited by 88

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

// Zhi-Jie Hou 1,* , Xi Luo 1,* , Wei Zhang 1,* , Fei Peng 1 , Bai Cui 1 , Si-Jin Wu 2 , Fei-Meng Zheng 1 , Jie Xu 1 , Ling-Zhi Xu 1 , Zi-Jie Long 3 , Xue-Ting Wang 1 , Guo-Hui Li 4 , Xian-Yao Wan 5 , Yong-Liang Yang 2 and Quentin Liu 1 1 Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China 2 Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, China 3 Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China 4 Laboratory of Molecular Modeling and Design, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, The Chinese Academy of Sciences, Dalian, China 5 Department of Critical Care Medicine, the First Affiliated Hospital, Dalian Medical University, Dalian, China * These authors contributed equally to this work Correspondence to: Quentin Liu, email: // Yong-liang Yang, email: // Xian-Yao Wan, email: // Keywords : flubendazole, breast cancer, cancer stem-like cell, cell cycle, tubulin Received : August 23, 2014 Accepted : January 05, 2015 Published : January 21, 2015 Abstract Cancer stem-like cell (CS-like cell) is considered to be responsible for recurrence and drug resistance events in breast cancer, which makes it a potential target for novel cancer therapeutic strategy. The FDA approved flubendazole, has been widely used in the treatment of intestinal parasites. Here, we demonstrated a novel effect of flubendazole on breast CS-like cells. Flubendazole inhibited breast cancer cells proliferation in dose- and time-dependent manner and delayed tumor growth in xenograft models by intraperitoneal injection. Importantly, flubendazole reduced CD44 high /CD24 low subpopulation and suppressed the formation of mammosphere and the expression of self-renewal related genes including c-myc , oct4 , sox2, nanog and cyclinD1 . Moreover, we found that flubendazole induced cell differentiation and inhibited cell migration. Consistently, flubendazole reduced mesenchymal markers (β-catenin, N-cadherin and Vimentin) expression and induced epithelial and differentiation marker (Keratin 18) expression in breast cancer cells. Mechanism study revealed that flubendazole arrested cell cycle at G2/M phase and induced monopolar spindle formation through inhibiting tubulin polymerization. Furthermore, flubendazole enhanced cytotoxic activity of conventional therapeutic drugs fluorouracil and doxorubicin against breast cancer cells. In conclusion, our findings uncovered a remarkable effect of flubendazole on suppressing breast CS-like cells, indicating a novel utilization of flubendazole in breast cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3436

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Hou, Z.-J., Luo, X., Zhang, W., Peng, F., Cui, B., Wu, S.-J., Zheng, F.-M., Xu, J., Xu, L.-Z., Long, Z.-J., Wang, X.-T., Li, G.-H., Wan, X.-Y., Yang, Y.-L., & Liu, Q.
Venue
Oncotarget
Published
2015-01-21
Volume
6
Issue
8
Pages
6326-6340
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1654551777
Cited by
88
References
6
FWCI
3.51
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.